Meningiomas usually grow slowly and go unnoticed for a long time. Symptoms often only arise as a result of pressure on neighboring brain structures and can include headaches, visual disturbances, speech difficulties or paralysis.

The most important examination is magnetic resonance imaging (MRI) with contrast medium. In addition, special procedures such as perfusion MRI, MR spectroscopy or amino acid PET can be used. The diagnosis is confirmed by a tissue examination. An important molecular marker is MGMT promoter methylation, which provides an indication of the response to chemotherapy with temozolomide.

The treatment aims to achieve the best possible tumor control while preserving functions. This involves a multi-stage therapy:

1. Surgery - complete, safe removal of the tumor as far as the location allows. Numerous state-of-the-art procedures are used here in order to spare the healthy nerve tissue as much as possible.
2. Radio-chemotherapy - a short course of daily radiotherapy combined with chemotherapy with temozolomide for 6 weeks.
3. This is followed by temozolomide maintenance therapy in 6 cycles (5 days every 4 weeks for a total of 6 months).

In the event of recurrence, further surgery, radiotherapy, medication or participation in clinical trials may be appropriate.

Glioblastoma is a serious disease. The course and prognosis depend on factors such as age, general condition, extent of removal and MGMT methylation. In addition to controlling the disease for as long as possible, an important goal is to maintain quality of life through accompanying therapies and individual support.

Possible signs can include epileptic seizures, headaches, speech or vision problems, numbness, paralysis and changes in memory, concentration or personality - depending on where the tumor is located and how large it is.

Magnetic resonance imaging (MRI) with contrast medium is central; if necessary, we supplement this with procedures such as perfusion MRI, MR spectroscopy or amino acid PET. The diagnosis is confirmed by a tissue examination. In addition, we examine tumor biological characteristics that are important for therapy planning and aftercare.

Treatment is discussed individually with our patients based on the recommendations of our interdisciplinary tumor board. The cornerstones are

1. Surgery: preferably a "maximum safe resection" to reduce tumor mass, reduce seizures and obtain tissue for analysis; modern navigation, mapping and monitoring procedures protect healthy brain tissue.
2. Observation vs. follow-up treatment: after complete removal and a favorable initial situation, close MRI checks (usually every 3-6 months) may initially suffice.
3. Radiotherapy and/or chemotherapy or targeted therapy: in the case of residual tumor, higher risk or progression, radiotherapy and drug treatment (e.g. with temozolomide or vorasidenib) are used; the choice depends on the individual situation, tumor grade, age and general condition.

We also treat epilepsy and other symptoms in a targeted manner and incorporate neurorehabilitation at an early stage.

The course is very individual and depends, among other things, on age, general condition, tumor location, extent of removal and tumor biology characteristics. A generous, function-preserving resection can delay the risk of progression.

Epileptic seizures are typical. Depending on the location, headaches, speech or visual disturbances, paralysis, sensory disturbances and changes in attention, memory, drive or personality may also occur.

Magnetic resonance imaging (MRI) with contrast medium is central. If necessary, we supplement this with special procedures such as perfusion MRI, MR spectroscopy or amino acid PET. The diagnosis is confirmed by a tissue examination; we also examine tumor biological characteristics that are relevant for therapy planning and aftercare.

Treatment is discussed individually with our patients based on the recommendations of our interdisciplinary tumor board. The cornerstones are

1. Surgery - the aim is to achieve a "maximum safe resection" in order to reduce tumor mass, improve seizures and obtain tissue for analysis. Modern navigation, mapping and monitoring procedures protect healthy brain tissue.
2. Observation vs. follow-up treatment - after complete removal and a favorable initial situation, close MRI checks (usually every 3-6 months) may initially be sufficient.
3. Radiotherapy and/or chemotherapy or targeted therapy: in the case of residual tumor, higher risk or progression, radiotherapy and drug treatment (e.g. according to the "PCV scheme" or vorasidenib) are used; the choice depends on the individual situation, tumor grade, age and general condition.

We also treat seizures and other symptoms in a targeted manner and incorporate neurorehabilitation at an early stage.

The overall course is often more favorable than with other diffuse gliomas, but varies greatly from individual to individual. It depends, among other things, on age, general condition, tumor location, extent of removal and tumor biological characteristics. Regular MRI checks are important in the long term.